Regulatory Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings Pharmaceutical TechnologyThe EMA's CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.RegulatoryRead full story pharminent April 24, 2026 (Last updated: April 24, 2026) Pharmaceutical Technology The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases. RegulatoryRead full story Post navigation Previous: Daiichi Sankyo shares slip after delaying annual earnings reportNext: Gene therapy leaders aim to help more Baby KJs with novel regulatory models Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026